🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nanjing
Clinical trial register · China

Clinical Trials in Nanjing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Nanjing 201 Zhengzhou 5 Beijing 5 Changzhou 5 Suzhou 3
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University201 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School89 Nanjing First Hospital, Nanjing Medical University68 The Second Hospital of Nanjing Medical University32 Nanjing Medical University30 Clear sponsor filter
Site location
Nanjing201 Zhengzhou5 Beijing5 Changzhou5 Suzhou3
All 31 locations
Target enrolment
to

Trials with a site in Nanjing

201 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
NCT07763938Relapsed/Refractory B-cell Malignancies
The First Affiliated Hospital with Nanjing Medical University
Phase 1
80
Nanjing
2026-11-01
Not yet open
Safety and Efficacy of Esketamine - Dexmedetomidine Combination Versus Dexmedetomidine Monotherapy for Hyperactive Delirium in ICU Patients on Non-Invasive Respiratory Support (SEED-NIRS Trial): Study Protocol of a Randomized Controlled Trial
NCT07377981Dexmedetomidine, Ketamine, Analgesia, Respiratory Therapy
The First Affiliated Hospital with Nanjing Medical University
Phase 4
356
Nanjing
2026-09-28
Not yet open
A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies
NCT07628582Relapsed/Refractory B-cell Malignancies
The First Affiliated Hospital with Nanjing Medical University
Phase 1
48
Nanjing
2026-09-15
Not yet open
Heart Rate Variability Changes and Postoperative Delirium After Major Abdominal Surgery
NCT07783464Postoperative Delirium (POD), Heart Rate Variability (HRV)
The First Affiliated Hospital with Nanjing Medical University
Observational
500
Nanjing
2026-09-01
Not yet open
ctDNA-MRD Monitoring After Neoadjuvant Therapy in Gastric Cancer With pCR or MPR
NCT07799649Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University
Observational
150
Nanjing
2026-09
Not yet open
Sino-Russian Comparison of Outcomes After Proximal Gastrectomy With Double-Tract Reconstruction
NCT07800819Gastric Adenocarcinoma, Adenocarcinoma of the Esophagogastric Junction
The First Affiliated Hospital with Nanjing Medical University
Observational
250
Nanjing
2026-08-15
Recruiting
Neoadjuvant Short-course Hypofractionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Locally Advanced Cervical Cancer: A Single-arm Phase II Trial
NCT07731828Cervical Neoplasms
The First Affiliated Hospital with Nanjing Medical University
Phase 2
35
Nanjing
2026-08-01
Not yet open
A Prospective Cohort Study on the Epidemiological Investigation, Diagnosis, and Treatment of Hepatic Encephalopathy
NCT07612670Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, Liver Cirrhosis
The First Affiliated Hospital with Nanjing Medical University
Observational
700
Nanjing
2026-08-01
Not yet open
The Efficacy of CAPCT in Patients With PTCL
NCT07746245Peripheral T-Cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
58
Nanjing
2026-08-01
Not yet open
Neoadjuvant SHR-A1811 and SHR-A1701 ± Pertuzumab for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma
NCT07716111Gastric or Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
24
Nanjing
2026-07-16
Recruiting
Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)
NCT07719556Mantle Cell Lymphoma (MCL)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
39
Changzhou, Nanjing
2026-07-15
Not yet open
Intra-arterial Thrombolysis For Acute Ischemic Stroke With Medium Vessel Occlusion
NCT07668323Medium Vessel Occlusion, Ischemic Stroke, Acute
The First Affiliated Hospital with Nanjing Medical University
Phase 3
306
Nanjing
2026-07-01
Not yet open
A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy
NCT07669740Gastric Cancer (Diagnosis)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
30
Nanjing
2026-07-01
Not yet open
Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma
NCT07628595Multiple Myeloma (MM)
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1
19
Nanjing
2026-07-01
Recruiting
Study on the Thrombolytic Effect of Platelet Membrane Coated Tenecteplase on Human Arterial Thrombus
NCT07712445Arterial Thrombosis
The First Affiliated Hospital with Nanjing Medical University
Observational
24
Nanjing
2026-06-30
Recruiting
A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.
NCT07622836TNBC, Adjuvant Therapy, Lymph Node Positive
The First Affiliated Hospital with Nanjing Medical University
Not applicable
59
Nanjing
2026-06-05
Not yet open
Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL
NCT07643805DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2
46
Nanjing
2026-06-01
Recruiting
A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients
NCT07671378CLL (Chronic Lymphocytic Leukemia)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
24
Nanjing
2026-06-01
Recruiting
Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes
NCT07608978Diffuse Large B-Cell Lymphoma (DLBCL)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
35
Nanjing
2026-06-01
Recruiting
Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC
NCT07646639Rectal Cancer, Radiotherapy
The First Affiliated Hospital with Nanjing Medical University
Phase 2
122
Nanjing
2026-05-20
Recruiting
Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases
NCT07558850Rheumatoid Arthritis, Dermatomyositis, Systemic Lupus Erythematosus, Systemic Sclerosis
The First Affiliated Hospital with Nanjing Medical University
Not applicable
72
Nanjing
2026-05-10
Not yet open
Neoadjuvant SHR-A1811 and SHR-A1701 for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma
NCT07581574Gastric or Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 1
12
Nanjing
2026-05-01
Not yet open
Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC
NCT07523789TNBC, Triple Negative Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Observational
201
Nanjing
2026-05-01
Recruiting
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
NCT07464756Gastric Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
80
Nanjing
2026-04-03
Recruiting
Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes
NCT07558863Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)
The First Affiliated Hospital with Nanjing Medical University
Phase 4
60
Nanjing
2026-04-01
Recruiting
Dihydroartemisinin for MAFLD
NCT07679542MAFLD
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2
30
Nanjing
2026-03-30
Recruiting
Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial
NCT07474324GC/GEJC
The First Affiliated Hospital with Nanjing Medical University
Phase 2
124
Nanjing
2026-03-15
Not yet open
A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)
NCT07471165Locally Advanced Perihilar Cholangiocarcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
25
Nanjing
2026-03-01
Not yet open
Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX
NCT07391826Stage III Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
48
Nanjing
2026-02-15
Not yet open
Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD
NCT07418177AMD - Age-Related Macular Degeneration
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2
9
Nanjing
2026-02-10
Not yet open
Intravascular Imaging-Guided Intravascular Lithotripsy for Severe Coronary Calcified Lesions.
NCT07444346Coronary Artery Calcification, Coronary Artery Disease
The First Affiliated Hospital with Nanjing Medical University
Observational
200
Nanjing
2026-02-10
Recruiting
Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
NCT07396454HER2-Negative Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
39
Nanjing
2026-02-10
Recruiting
PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.
NCT07410520Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
50
Nanjing
2026-02-07
Recruiting
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
NCT07418190Relapsed/Refractory Follicular Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
33
Nanjing
2026-02-01
Recruiting
Safety of Robotic Surgery for GISTs at Special Anatomic Sites
NCT07405125Gastrointenstinal Stromal Tumor (GIST)
The First Affiliated Hospital with Nanjing Medical University
Not applicable
182
Nanjing
2026-02-01
Not yet open
Robotic vs Laparoscopic Gastrectomy for cT4a Gastric Cancer
NCT07331454Gastric Cancer (GC)
The First Affiliated Hospital with Nanjing Medical University
Phase 3
335
Nanjing
2026-02-01
Not yet open
SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma
NCT07347288PTCL
The First Affiliated Hospital with Nanjing Medical University
Phase 2
30
Nanjing
2026-02
Recruiting
A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer
NCT07438106Locally Advanced Pancreatic Cancer With KRAS G12D Mutation
The First Affiliated Hospital with Nanjing Medical University
Phase 2
30
Nanjing
2026-01-28
Recruiting
7-Day Vonoprazan, High-Dose Amoxicillin, and Bismuth Therapy
NCT07232095Helicobacter Pylori
The First Affiliated Hospital with Nanjing Medical University
Phase 4
316
Nanjing
2026-01-08
Not yet open
QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer
NCT07315035Gastric Cancer Stage III
The First Affiliated Hospital with Nanjing Medical University
Phase 2
74
Nanjing
2026-01-01
By invitation
Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy
NCT07371247Esophageal Cancer, MRD, ctDNA
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1
65
Nanjing
2025-12-20
Recruiting
Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
NCT07277439Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
48
Nanjing
2025-12-16
Recruiting
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
NCT07294625Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1
36
Zhengzhou, Nanjing, Xuzhou, Shanghai, Xi’an
2025-12-10
Not yet open
Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer
NCT07277452Pancreatic Cancer, Adult
The First Affiliated Hospital with Nanjing Medical University
Phase 2
156
Nanjing, Beijing
2025-12-10
Recruiting
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
NCT06958705Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
79
Nanjing
2025-12-01
Active, closed
Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis
NCT07396467Lung Cancer (Diagnosis), Pulmonary Fibrosis, Interstitial Lung Diseases
The First Affiliated Hospital with Nanjing Medical University
Observational
200
Nanjing
2025-11-01
Recruiting
Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis
NCT07263425Leptomeningeal Metastasis of HER2-positive Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
26
Nanjing
2025-10-27
Recruiting
A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
NCT07263386Gastric Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
460
Nanjing
2025-10-23
Recruiting
An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies
NCT07668453Biliary Tract Neoplasms
The First Affiliated Hospital with Nanjing Medical University
Phase 2
30
Nanjing
2025-10-20
Not yet open
A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma.
NCT07156643Locally Advanced Soft Tissue Sarcoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
46
Nanjing
2025-10-01
Recruiting
An Exploratory Clinical Study on the Safety and Efficacy of Autologous NK Cells in the Treatment of Pulmonary Nodules
NCT07185035Pulmonary Nodules, Solitary, Pulmonary Nodules, Multiple
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1
24
Nanjing
2025-09-20
Not yet open
Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial
NCT07050524Gastric Cancer Stage III
The First Affiliated Hospital with Nanjing Medical University
Phase 2
80
Nanjing
2025-09-01
Not yet open
Rapid Detection of Pseudomonas Aeruginosa in Bronchoalveolar Lavage Fluid Using Label-free Single-particle Imaging Technology and Assessment of Post-treatment Efficacy in Patients With Pseudomonas Aeruginosa Infection
NCT06986512Rapid Detection, Pseudomonas Aeruginosa Infection
The First Affiliated Hospital with Nanjing Medical University
Observational
100
Nanjing
2025-09-01
Recruiting
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
NCT07240194Large B-cell Lymphoma, TP53
The First Affiliated Hospital with Nanjing Medical University
Phase 2
24
Nanjing
2025-09-01
Recruiting
Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer
NCT07718490Metastatic Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
43
Nanjing
2025-09-01
Not yet open
Study on Proteomic and Microbiome Changes in Patients With Hepatic Encephalopathy (HE)
NCT07150195Cirrhoses, Liver, Hepatic Encephalopathy (HE)
The First Affiliated Hospital with Nanjing Medical University
Observational
32
Nanjing
2025-09
Not yet open
Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS
NCT06925555EBV-Positive Diffuse Large B-Cell Lymphoma, Nos, Brentuximab Vedotin
The First Affiliated Hospital with Nanjing Medical University
Phase 2
25
Nanjing
2025-09
By invitation
Diagnostic Application of AI-ROSE in Severe Pneumonia
NCT07113951Severe Pneumonia, Bacterial Infections
The First Affiliated Hospital with Nanjing Medical University
Observational
100
Nanjing
2025-08-31
Not yet open
QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)
NCT07113964Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency
The First Affiliated Hospital with Nanjing Medical University
Phase 2
79
Nanjing
2025-08-30
Recruiting
RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies
NCT07105735Autoimmune Diseases Refractory to Standard Therapies
The First Affiliated Hospital with Nanjing Medical University
Phase 1
18
Nanjing
2025-08-15
Recruiting
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
NCT07208981Marginal Zone Lymphoma(MZL)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
169
Nanjing
2025-08-14
Not yet open
A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
NCT07131501Hepatocellular Carcinoma, Immunotherapy, Preoperative, PD-1
The First Affiliated Hospital with Nanjing Medical University
Phase 2
48
Nanjing
2025-08-11
Recruiting
AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT
NCT07250347Gastric Cancer Stage, Gastric Cancer Patients Undergoing Gastrectomy
The First Affiliated Hospital with Nanjing Medical University
Observational
8,000
Nanjing
2025-08-01
Not yet open
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
NCT07113496Relapsed or Refractory B-cell Hematologic Malignancies, B-cell Acute Lymphoblastic Leukemia (B-ALL), Multiple Myeloma (MM), Plasmablastic Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 1
27
Nanjing
2025-08
Not yet open
A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC
NCT06977828NSCLC (Non-small Cell Lung Cancer), Neoadjuvant Immunotherapy, Adjuvant Immunotherapy
The First Affiliated Hospital with Nanjing Medical University
Phase 2
40
Nanjing
2025-07-20
Recruiting
Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
NCT07126678Follicular Lymphoma, Treatment Naive
The First Affiliated Hospital with Nanjing Medical University
Not applicable
15
Nanjing
2025-07-15
Recruiting
Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT
NCT07309211SCLC, Limited Stage
The First Affiliated Hospital with Nanjing Medical University
Observational
25
Jinan, Nanjing, Qingdao
2025-07-08
Not yet open
Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis
NCT06779318Pancreatic Cancer, Postoperative Adjuvant Therapy, Maintenance Therapy
The First Affiliated Hospital with Nanjing Medical University
Phase 4
464
Nanjing
2025-07
Not yet open
A Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets)
NCT06895460Bronchial Asthma
The First Affiliated Hospital with Nanjing Medical University
Phase 3
198
Nanjing
2025-06-20
Recruiting
The Risk Factors Related to Rupture Flow-related Aneurysms in Posterior AVM
NCT07050381Arteriovenous Malformation of Central Nervous System, Aneurysm, Ruptured, Aneurysmatic Subarachnoid Haemorrhage, Aneurysm Cerebral
The First Affiliated Hospital with Nanjing Medical University
Observational
200
Nanjing
2025-06-13
Recruiting
The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
NCT07002112Relapsed/Refractory B-cell Malignancies
The First Affiliated Hospital with Nanjing Medical University
Phase 1
30
Hefei, Beijing, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2025-05-23
Recruiting
An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis
NCT06613490Antisynthetase Syndrome, Rheumatoid Arthritis
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1
24
Nanjing
2025-05-20
By invitation
A Study of GD007 (Human iPSC-Exosome Liquid Dressing) for Safety and Dose-Finding in Moderate-Severe Intrauterine Adhesions
NCT07101484Moderate-Severe Intrauterine Adhesions
The First Affiliated Hospital with Nanjing Medical University
Not applicable
29
Nanjing
2025-05-04
Recruiting
A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer
NCT07455019Esophageal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
28
Nanjing
2025-05-01
Recruiting
VA Dual Sequential Therapy
NCT06929962Helicobacter Pylori Infection
The First Affiliated Hospital with Nanjing Medical University
Phase 4
600
Nanjing
2025-04-24
Not yet open
Effect of ADT and ARPI on Bone Loss of Patients with Prostate Cancer
NCT06838520Prostate Cancer (Adenocarcinoma)
The First Affiliated Hospital with Nanjing Medical University
Observational
200
Changzhou, Nanjing, Suzhou, Yangzhou
2025-04-01
Recruiting
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
NCT07448324Marginal Zone Lymphoma(MZL)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
50
Nanjing
2025-04-01
Recruiting
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
NCT06838910Thymic Carcinoma, Thymoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
20
Nanjing
2025-03-31
Recruiting
Study on the Optimization of the Diagnostic Process for Chronic Rhinitis Using Nasal Allergen Provocation Test
NCT06999044Chronic Rhinitis
The First Affiliated Hospital with Nanjing Medical University
Observational
100
Nanjing
2025-03-24
Not yet open
Effect of Digital Therapeutics for Cardiac Rehabilitation in Patients With Acute Myocardial Infarction
NCT06772337Acute Myocardial Infarction, Cardiac Rehabilitation
The First Affiliated Hospital with Nanjing Medical University
Not applicable
160
Nanjing
2025-03-01
Recruiting
A Multicenter Prospective Randomized Controlled Clinical Trial Comparing Constant (5%) Versus Sequential (5%-2%) Oxygen Concentration Embryo Culture Protocols in Assisted Reproductive Technology
NCT07050537Fertility Issues, Blastocyst IVF, Embryo Culture
The First Affiliated Hospital with Nanjing Medical University
Not applicable
980
Zhengzhou, Changzhou, Nanjing, Suzhou, Xi’an
2025-03-01
Not yet open
Risk Prediction Model of MACE in Patients With AMI Based on Multi-modal Machine Learning
NCT06767852Acute Myocardial Infarction
The First Affiliated Hospital with Nanjing Medical University
Observational
655
Nanjing
2025-03-01
Recruiting
Gestational Lifestyle & Outcomes Wellness
NCT07263412GDM
The First Affiliated Hospital with Nanjing Medical University
Observational
1,000
Nanjing
2025-02-25
Recruiting
A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11
NCT06759636CTIT: Cancer Therapy Induced Thrombocytopenia
The First Affiliated Hospital with Nanjing Medical University
Phase 3
88
Nanjing
2025-02-24
Recruiting
A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing
NCT07036731Non Muscle Invasive Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University
Not applicable
428
Nanjing
2025-02-01
Recruiting
Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery
NCT06762782Hepatocellular Carcinoma (HCC), Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation
The First Affiliated Hospital with Nanjing Medical University
Phase 2
276
Nanjing
2025-02
Recruiting
Hypofractionated Radiation Fractionation in Breast Cancer Patients With Implant-Based Reconstruction
NCT06830083Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Not applicable
840
Nanjing
2025-01-30
Recruiting
Prospective Study on Exemption of Tumor Bed Boost Radiotherapy for pCR Patients After Breast Conserving Surgery With Neoadjuvant Therapy
NCT07113613Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
150
Nanjing
2025-01-01
Recruiting
To Evaluate the Effectiveness and Safety of Mastectomy Combined With Immediate Breast Reconstruction in Breast Cancer (NJMU-Reconstruction Cohort)
NCT06817954Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Not applicable
800
Nanjing
2025-01-01
Recruiting
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
NCT07394387Triple Negative Breast Cancer (TNBC)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
58
Nanjing
2025-01-01
Recruiting
Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL
NCT07195799Non-Hodgkin Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
180
Nanjing
2024-12-31
Recruiting
Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases
NCT06715007Stroke, Ischemic, Small Vessel Cerebrovascular Disease, White Matter Hyperintensity
The First Affiliated Hospital with Nanjing Medical University
Observational
300
Nanjing
2024-12-20
Not yet open
Microbial Study of Sublingual Immunotherapy Tablets in Patients With Allergic Rhinitis
NCT06741800Rhinitis, Allergic
The First Affiliated Hospital with Nanjing Medical University
Observational
100
Nanjing
2024-12-20
Not yet open
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC
NCT06699498Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, PD-L1, Anlotinib
The First Affiliated Hospital with Nanjing Medical University
Phase 2
45
Nanjing
2024-12-03
Active, closed
Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer
NCT06939439Gastric Cancer Stage III
The First Affiliated Hospital with Nanjing Medical University
Phase 3
416
Nanjing
2024-12-01
Recruiting
A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer
NCT06735287Bladder Cancer, NMIBC
The First Affiliated Hospital with Nanjing Medical University
Not applicable
60
Nanjing
2024-12-01
By invitation
Correlation Analysis of Xpert Carba-R Detection of Non-colonized CRE in BALF and Rectal Swabs From Patients With LRTI
NCT06636890Carbapenem-Resistant Enterobacteriaceae, Lower Respiratory Tract Infections
The First Affiliated Hospital with Nanjing Medical University
Observational
200
Nanjing
2024-12-01
Recruiting
Prospective Study on the Safety and Efficacy of Robot-Assisted Laparoscopic Partial Nephrectomy With Renal Artery Off-Clamp in the Treatment of cT1 Renal Tumors
NCT06908902RCC, Renal Cell Cancer, Partial Nephrectomy
The First Affiliated Hospital with Nanjing Medical University
Not applicable
60
Nanjing
2024-12-01
Recruiting
Comparing the Incidence of Parastomal Hernia After Mesenteric Molding Suturing and Non-molding Suturing in Colostomy Surgery
NCT06674187Parastomal Hernia
The First Affiliated Hospital with Nanjing Medical University
Not applicable
234
Nanjing
2024-12-01
Not yet open
Microbial Study of Sublingual Immunotherapy Spray in Patients With Allergic Rhinitis
NCT06741787Rhinitis, Allergic
The First Affiliated Hospital with Nanjing Medical University
Observational
100
Nanjing
2024-12
Rows per page Showing 1–100 of 201
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/nanjing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 201 of those studies with a site in Nanjing that also match the filters currently applied.

How many clinical trials are recruiting in Nanjing?

130 of the 201 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 51 have not yet opened recruitment, 12 are active but closed to new participants, and 8 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nanjing), 201 studies
PhaseStudiesRecruitingShare
Phase 2684833.8%
Not applicable483523.9%
Observational442221.9%
Phase 31286%
Phase 4964.5%
Phase EARLY_PHASE1854%
Phase 1733.5%
Phase 1/2532.5%

Most active sponsors

Lead sponsors with the most studies (Nanjing)
Lead sponsorStudiesRecruiting
The First Affiliated Hospital with Nanjing Medical University201130
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.